Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
September 11 2024 - 4:04PM
UK Regulatory
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public
Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE
NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a
clinical-stage pharmaceutical company that aims to discover and
develop medicines that are transformational for patients, today
announced that it has commenced an underwritten public offering of
$150 million of American Depositary Shares (“ADSs”), each
representing one ordinary share. All of the ADSs are being offered
by Centessa. In addition, Centessa intends to grant the
underwriters a 30-day option to purchase up to an additional $22.5
million of ADSs offered in the public offering. The proposed
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Leerink Partners,
Evercore ISI, Guggenheim Securities and BMO Capital Markets are
acting as joint book-running managers for the offering.
The ADSs are being offered pursuant to a
registration statement on Form S-3 that was filed with the
Securities and Exchange Commission (“SEC”) on September 11, 2024
and became automatically effective upon filing. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offering, when available, may be obtained from:
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, telephone: (866) 471-2526, email:
prospectus-ny@ny.email.gs.com; Leerink Partners LLC, Syndicate
Department, 53 State Street, 40th Floor, Boston, MA 02109,
telephone: (800) 808-7525 ext. 6105, email: syndicate@leerink.com;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, telephone: (888)
474-0200, email: ecm.prospectus@evercore.com; Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, 8th Floor, New York, NY 10017,
telephone: (212) 518-9544, email:
GSEquityProspectusDelivery@guggenheimpartners.com; or BMO Capital
Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd
Street, 32nd Floor, New York, NY 10036, email:
bmoprospectus@bmo.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Centessa
Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical
company that aims to discover and develop medicines that are
transformational for patients. Our most advanced programs include a
hemophilia program, an orexin agonist program for the treatment of
narcolepsy and other sleep-wake disorders, and an immuno-oncology
program focused on our LockBody® technology platform. We operate
with the conviction that each of our programs has the potential to
change the current treatment paradigm and establish a new standard
of care.
Forward Looking Statements
This press release contains forward-looking statements. Any such
statements in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including those relating to Centessa’s expectations regarding the
completion, timing and size of the public offering and its
expectations with respect to granting the underwriters a 30-day
option to purchase additional ADSs. Any forward-looking statements
in this press release are based on our current expectations,
estimates and projections only as of the date of this release and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties related to completion of the proposed public
offering on the anticipated terms, or at all, include, but are not
limited to, market conditions and the satisfaction of customary
closing conditions related to the proposed public offering. Risks
concerning our programs and operations are described in additional
detail in our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and our other reports, which are on file with the U.S.
Securities and Exchange Commission. We explicitly disclaim any
obligation to update any forward-looking statements except to the
extent required by law.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (TG:260)
Historical Stock Chart
From Nov 2024 to Dec 2024
Centessa Pharmaceuticals (TG:260)
Historical Stock Chart
From Dec 2023 to Dec 2024
